The complexity of software architecture and diverse user interactions presents challenges to conventional testing approaches. Traditional test automation and quality assurance engineering represented ...

Next-generation sequencing (NGS) has become increasingly popular with testing laboratories allowing them to obtain more data in less time and with minimal input. In this webinar we will explore the ...

The US Food and Drug Administration (FDA) on Wednesday finalized guidance to help industry develop and validate immune assays for the assessment of the immunogenicity of therapeutic protein products ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of ...

Acquired CARD11 Mutation Promotes BCR Independence in Diffuse Large B Cell Lymphoma Despite the well-understood benefits of biomarker and genetic testing in precision medicine, uptake remains low, ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

For people with stable chest pain, a personalized "precision" testing approach led to more efficient evaluations for heart disease risk and improved diagnosis and treatment of coronary artery disease ...

BD-pTau 217 is a refined biomarker which enhances Alzheimer’s specificity while retaining the strengths of plasma pTau 217.

Chunghwa Precision Test Tech. completed its board election at the 2026 annual shareholders' meeting on May 27 as the ...